The adrenal glands, small triangular organs perched atop each kidney, are central to the body’s stress response, metabolism, and blood pressure regulation. They produce cortisol, aldosterone, catecholamines, and androgens—hormones that directly influence glucose homeostasis. When these glands malfunction, the resulting hormonal imbalances can create a clinical picture that closely resembles diabetes mellitus, or significantly worsen glycemic control in patients already diagnosed with diabetes. This overlap often leads to diagnostic delays, inappropriate treatment, and increased risk of complications. Understanding the specific adrenal disorders that can mimic or exacerbate diabetes is essential for clinicians and patients alike.

Recognizing these disorders is particularly important because the symptoms—fatigue, weight changes, high or low blood sugar, and blood pressure fluctuations—are common to both conditions. Without targeted evaluation, adrenal disease may go untreated while diabetes management remains suboptimal. This article explores the major adrenal gland disorders that affect glucose metabolism, how they present, and the steps needed to differentiate them from primary diabetes.

Common Adrenal Gland Disorders That Affect Diabetes Symptoms

1. Cushing’s Syndrome: The Cortisol Excess Problem

Cushing’s syndrome results from prolonged exposure to elevated levels of cortisol. This can occur from an adrenal tumor (adenoma or carcinoma) that autonomously secretes cortisol, from excess ACTH production by a pituitary tumor (Cushing’s disease), or from exogenous corticosteroid use. Cortisol is a potent counter-regulatory hormone that opposes insulin action, leading to insulin resistance and impaired glucose uptake in peripheral tissues.

Impact on glucose metabolism: Increased cortisol stimulates gluconeogenesis in the liver, reduces glucose uptake in muscle and fat, and promotes lipolysis. These effects raise fasting and postprandial blood glucose levels. As many as 40–60% of patients with Cushing’s syndrome develop impaired glucose tolerance or frank diabetes mellitus. The diabetes seen in Cushing’s is often characterized by significant insulin resistance, requiring high doses of insulin or multiple oral agents.

Overlapping symptoms: Patients with Cushing’s syndrome experience central obesity, facial rounding (moon face), supraclavicular fat pads, thin skin, easy bruising, proximal muscle weakness, and hypertension. These features overlap with type 2 diabetes, especially when obesity is present. However, the presence of purple striae, buffalo hump, and marked skin fragility points toward cortisol excess rather than simple obesity-related diabetes.

Diagnostic clues: The following findings should raise suspicion for Cushing’s syndrome in a patient with diabetes: uncontrolled hyperglycemia despite aggressive therapy, unexplained osteoporosis, hypokalemia, or features of hypercortisolism on physical exam. Initial screening tests include the 1 mg overnight dexamethasone suppression test, 24-hour urinary free cortisol, and late-night salivary cortisol. Confirmatory testing and imaging (pituitary MRI, adrenal CT) are required to localize the source.

Treatment: Curative surgery (resection of pituitary or adrenal tumor) is preferred. If surgery is not possible, medical therapy with steroidogenesis inhibitors (e.g., ketoconazole, metyrapone) or glucocorticoid receptor antagonists (mifepristone) may be used. In exogenous cases, tapering or discontinuing corticosteroids is indicated. After successful treatment, glucose tolerance often improves dramatically, and many patients can reduce or discontinue diabetes medications.

2. Addison’s Disease: The Cortisol Deficiency Risk

Addison’s disease (primary adrenal insufficiency) is characterized by destruction of the adrenal cortex, leading to deficient production of cortisol and aldosterone. Autoimmune adrenalitis is the most common cause in developed countries; infectious causes (tuberculosis, fungal infections) and bilateral adrenal hemorrhage are less common. In secondary adrenal insufficiency (from pituitary or hypothalamic disease), aldosterone production is usually preserved, but cortisol deficiency still poses risks.

Impact on glucose metabolism: Cortisol deficiency removes the counter-regulatory response to insulin, making patients prone to hypoglycemia, especially during fasting, illness, or exercise. Loss of aldosterone leads to sodium wasting, volume depletion, and hyperkalemia, further complicating glucose regulation by impairing renal function and altering medication pharmacokinetics.

Overlapping and contrasting symptoms: The classic symptoms of Addison’s—fatigue, weight loss, hyperpigmentation of skin and mucous membranes, orthostatic hypotension—can be misinterpreted as poor diabetes control, especially if the patient experiences frequent hypoglycemic episodes. The hallmark of Addison’s is unexplained hypoglycemia in a patient with diabetes, often with minimal or no symptoms of autonomic response (since epinephrine release may also be blunted in chronic adrenal insufficiency). Hyperkalemia and hyponatremia on routine labs are additional red flags that should prompt adrenal testing.

Diagnostic approach: Measurement of morning serum cortisol and ACTH is the first step. A low cortisol level with elevated ACTH confirms primary adrenal insufficiency. The cosyntropin (ACTH) stimulation test is the gold standard. In secondary adrenal insufficiency, both cortisol and ACTH are low. Imaging of the adrenal glands may show atrophy or calcifications.

Treatment and interaction with diabetes management: Lifelong glucocorticoid replacement (hydrocortisone, prednisone) and, in primary disease, mineralocorticoid replacement (fludrocortisone) are essential. The challenge lies in balancing steroid dosing: too little steroid leads to hypoglycemia and adrenal crisis; too much steroid causes hyperglycemia and mimics Cushing’s syndrome. Patients with diabetes and Addison’s disease require careful coordination of steroid timing with meals and insulin doses. Sick-day rules (stress dosing) must be clearly communicated to avoid adrenal crisis, which can present as severe hypoglycemia and shock.

3. Pheochromocytoma: Catecholamine Crisis and Hyperglycemia

Pheochromocytoma is a rare catecholamine-secreting tumor of the adrenal medulla (or extra-adrenal paraganglia). The excessive release of epinephrine and norepinephrine causes dramatic swings in blood pressure, palpitations, headache, and sweating. These catecholamines also promote glycogenolysis, gluconeogenesis, and lipolysis, leading to pronounced hyperglycemia during paroxysms and even persistent diabetes in some patients.

Presentation in diabetes: A patient with diabetes who experiences episodes of hypertension, tachycardia, and anxiety—especially if accompanied by severe hyperglycemia that is episodic—should be evaluated for pheochromocytoma. The rapid rise in blood glucose during a catecholamine surge may be misattributed to poor dietary compliance or stress. Between attacks, glucose tolerance may be normal or mildly impaired.

Diagnosis: Measurement of plasma or urinary metanephrines and catecholamines is highly sensitive. Imaging with CT or MRI of the abdomen reveals the tumor. Genetic testing is recommended, as up to 40% of cases are associated with hereditary syndromes (e.g., MEN2, VHL, NF1).

Management: Surgical resection of the tumor is curative but requires preoperative preparation with alpha-adrenergic blockade (e.g., phenoxybenzamine) followed by beta-blockade to prevent hypertensive crisis during surgery. After successful removal, blood glucose levels often return to normal if the tumor was the sole cause of diabetes. Persistent hyperglycemia may indicate underlying insulin resistance unmasked by the catecholamine episodes.

Other Relevant Disorders

4. Adrenal Tumors: Functional and Non-Functional Effects

Adrenal masses are increasingly discovered incidentally on imaging (incidentalomas). Most are non-functional adenomas, but up to 5–10% secrete hormones such as cortisol (subclinical Cushing’s), aldosterone, or catecholamines. Even clinically silent cortisol-secreting adenomas can worsen glycemic control. Patients with an adrenal incidentaloma and diabetes should undergo evaluation for autonomous cortisol secretion (ACTH-independent hypercortisolism). Surgical removal of a functional adenoma often improves diabetes control.

Large or malignant tumors may produce multiple hormones or cause mass effect, further complicating management. Evaluation includes hormonal workup (cortisol, aldosterone/renin ratio, metanephrines) and imaging characteristics on CT or MRI. For non-functional adenomas, watchful waiting is appropriate, but diabetes patients should be monitored for development of hypercortisolism over time.

5. Congenital Adrenal Hyperplasia (CAH)

CAH is a group of autosomal recessive disorders caused by deficiency of enzymes involved in cortisol synthesis. The most common form is 21-hydroxylase deficiency. Impaired cortisol production leads to loss of negative feedback on the pituitary, increasing ACTH drive, which in turn stimulates adrenal androgen production. Aldosterone synthesis may also be compromised in salt-wasting forms.

Glucose implications: Although CAH primarily affects children, persistent cortisol deficiency in adults can cause recurrent hypoglycemia, especially during stress. Conversely, glucocorticoid therapy used to suppress ACTH and androgen excess can cause hyperglycemia and weight gain, mimicking diabetes. Patients with CAH who have diabetes require careful steroid titration. Androgen excess, particularly in women, contributes to insulin resistance and metabolic syndrome.

Diagnosis: Elevated levels of 17-hydroxyprogesterone (17-OHP) in response to ACTH stimulation confirm the diagnosis. Genetic testing identifies the specific mutation. In adults with diabetes, CAH should be considered if there is a history of ambiguous genitalia at birth, precocious puberty, short stature, infertility, or unexplained hypoglycemia in childhood.

Management: Glucocorticoid replacement (hydrocortisone, prednisone) is titrated to normalize ACTH and androgen levels while avoiding overtreatment. Mineralocorticoid replacement is added in salt-wasting forms. Women with CAH and insulin resistance may benefit from metformin. Regular screening for glucose intolerance is recommended.

Implications for Diagnosis and Treatment

Clinical Evaluation: When to Suspect an Adrenal Disorder

Healthcare providers should maintain a high index of suspicion in the following scenarios:

  • Unexplained hypoglycemia in a patient with diabetes, especially if recurrent or severe and not explained by medication mismatch, dietary changes, or renal impairment.
  • Refractory hyperglycemia despite escalating doses of insulin or multiple oral agents, particularly with features of central obesity, hypertension, and easy bruising.
  • Paroxysmal symptoms (palpitations, headache, sweating) with hypertension and hyperglycemia.
  • Electrolyte abnormalities such as hypokalemia (Cushing’s, hyperaldosteronism) or hyperkalemia with hyponatremia (Addison’s).
  • Incidental adrenal mass found on imaging, requiring hormonal evaluation.

A thorough history and physical exam are critical: review of medication history (including inhaled or topical steroids), family history of endocrine disorders, and associated genetic syndromes. Key physical findings include pigmentation in Addison’s, striae and central obesity in Cushing’s, and hypertensive episodes in pheochromocytoma.

Laboratory and Imaging Workup

Initial screening tests should be tailored to the suspected disorder:

  • Suspected Cushing’s: 1 mg overnight dexamethasone suppression test, 24-hour urinary free cortisol, late-night salivary cortisol.
  • Suspected Addison’s: Morning cortisol and ACTH; cosyntropin stimulation test if indeterminate.
  • Suspected pheochromocytoma: Plasma or urinary metanephrines and catecholamines.
  • Adrenal incidentaloma: Hormonal assessment as above, plus plasma aldosterone concentration/renin activity for primary hyperaldosteronism if hypertensive and hypokalemic.

Imaging: High-resolution CT of the adrenal glands with attenuation values helps characterize masses. MRI can be used for pheochromocytoma (T2 hyperintensity). In suspected Cushing’s disease, pituitary MRI with contrast is needed. Functional imaging (e.g., MIBG scan) is sometimes used for pheochromocytoma.

Treatment, Medication Adjustments, and Coordination of Care

Management of adrenal disorders in patients with diabetes requires an interdisciplinary approach involving endocrinologists, primary care providers, and diabetes educators. Key principles include:

  • For Addison’s: Glucocorticoid replacement should be adjusted to mimic natural circadian rhythm; morning doses highest. Stress dosing guidelines must be provided. Diabetes medications, especially insulin and sulfonylureas, may need dose reduction to prevent hypoglycemia. Self-monitoring of blood glucose is essential.
  • For Cushing’s: Surgical correction often leads to rapid improvement in insulin sensitivity; postoperative glucose levels must be monitored closely to avoid hypoglycemia. After remission, many patients can discontinue diabetes medications entirely.
  • For pheochromocytoma: Preoperative alpha-blockade is critical; beta-blockers should only be added after alpha-blockade to prevent unopposed alpha-mediated vasoconstriction. During surgery, continuous glucose monitoring is prudent because of massive catecholamine release and subsequent drop.
  • For CAH: Glucocorticoid doses should be titrated to maintain normal androgen levels while avoiding overtreatment. In patients with diabetes, insulin and oral agents may need adjustment as steroids are optimized.

Each of these disorders requires lifelong follow-up, especially after surgery or medication changes. Patients should be educated about symptoms of adrenal crisis or hormone excess and carry medical alert identification.

Why Awareness Matters: Reducing Diagnostic Errors and Improving Outcomes

The ability of adrenal disorders to mimic or exacerbate diabetes symptoms is a well-documented clinical phenomenon, yet it remains underrecognized. A systematic review of adrenal incidentalomas found that subclinical hypercortisolism is present in 5–30% of cases, many of whom have diabetes or prediabetes. Failure to identify the underlying adrenal cause can lead to years of suboptimal diabetes management, exposing patients to the risks of polypharmacy, hypoglycemia, and progressive complications.

Conversely, diagnosing an adrenal disorder can transform a patient’s clinical course. In a patient with Cushing’s syndrome who undergoes successful adrenalectomy, diabetes can go into remission. In Addison’s disease, appropriate glucocorticoid replacement stabilizes blood glucose and prevents life-threatening adrenal crises. For those with pheochromocytoma, surgical cure eliminates the source of unpredictable hyperglycemia and hypertensive surges.

Clinicians should therefore view unexplained difficulty in glycemic control—whether hyperglycemia or hypoglycemia—as an opportunity to consider the adrenal axis. Simple screening tests, when guided by clinical suspicion, can uncover treatable conditions that profoundly improve quality of life and reduce healthcare burden.

Conclusion

The adrenal glands exert powerful control over glucose metabolism. Disorders that disturb their hormone output—Cushing’s syndrome, Addison’s disease, pheochromocytoma, adrenal tumors, and congenital adrenal hyperplasia—can all present with or worsen diabetes symptoms. A thorough understanding of these connections, astute clinical assessment, and appropriate testing are essential for accurate diagnosis and effective treatment. Integrating adrenal health into diabetes care not only improves glycemic outcomes but also safeguards patients from the dangers of unrecognized endocrine disease.

For further reading, consult the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) guide on adrenal insufficiency and the Endocrine Society Clinical Practice Guidelines for Cushing’s syndrome. Additional resources for pheochromocytoma management can be found through the National Cancer Institute. For clinicians, the Mayo Clinic and Diabetes UK offer patient-centered advice on managing these complex coexisting conditions.